Arcus Biosciences (RCUS) vs Xenon Pharmaceuticals (XENE)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Arcus Biosciences (RCUS) has outperformed Xenon Pharmaceuticals (XENE) over the past year, gaining 74.8% versus a loss of 7.0%. Over five years, XENE leads with a +8.2% price change compared with -28.7% for RCUS. Xenon Pharmaceuticals is the larger company by market cap ($3.47 billion vs $2.93 billion), about 1.2 times the size.
Arcus Biosciences converts more of its revenue into profit, with a net margin of -142.9% versus -4612.1%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | RCUS | XENE |
|---|---|---|
| Share price | $23.28 | $35.83 |
| Market cap | $2.93B | $3.47B |
| 1-day change | -5.06% | -1.59% |
| YTD return | +2.90% | -18.76% |
| 1-year return | +74.77% | -7.02% |
| 5-year return | -28.70% | +8.17% |
| EPS (TTM) | $-3.91 | $-4.74 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $247.00M | $7.50M |
| Revenue growth (YoY) | -4.26% | — |
| Net income (latest FY) | $-353.00M | $-345.91M |
| Operating margin | -156.28% | -4974.27% |
| Net margin | -142.91% | -4612.13% |
| 52-week high | $31.74 | $72.66 |
| 52-week low | $14.26 | $35.06 |
| Distance from 52-week high | -26.64% | -50.69% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +71.43% | +104.77% |
| Average volume | 1.32M | 1.43M |
| Shares outstanding | 125.77M | 96.84M |
| Employees | 601 | 358 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- RCUS has outperformed XENE by 81.8 percentage points over the past year.
- Arcus Biosciences is more profitable, keeping -142.9 cents of every revenue dollar as net income versus -4612.1 cents for Xenon Pharmaceuticals.
About Arcus Biosciences
RCUS stock →Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Health Care · Biotechnology: Pharmaceutical Preparations · 601 employees
About Xenon Pharmaceuticals
XENE stock →Xenon Pharmaceuticals Inc., a neuroscience-focused biopharmaceutical company, engages in the discovery, development, and delivery of therapeutics to treat patients with neurological and psychiatric disorders. Its product candidates include Azetukalner, a novel, potent Kv7 potassium channel opener which is in Phase 3 clinical development for the treatment of epilepsy, including focal onset seizures, and primary generalized tonic-clonic seizures, as well as neuropsychiatric disorders, such as major depressive disorder and bipolar depression.
Health Care · Biotechnology: Pharmaceutical Preparations · 358 employees
RCUS vs XENE FAQ
Which is bigger, Arcus Biosciences or Xenon Pharmaceuticals?
Xenon Pharmaceuticals (XENE) is larger, with a market capitalization of $3.47B compared with $2.93B for Arcus Biosciences (RCUS).
Which stock has performed better over the past year, RCUS or XENE?
RCUS returned +74.77% over the past 12 months, compared with -7.02% for XENE (price return, excluding dividends). Past performance does not predict future results.
Are Arcus Biosciences and Xenon Pharmaceuticals in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.